Abstract
Erythropoietin is the endogenous hormone controlling red blood cell production. Most is made in the kidneys; if they fail, erythropoietin levels fall and anaemia develops. Treatment of erythropoietin deficiency anaemia in patients with renal failure has depended on repeated blood transfusions. Despite transfusions most patients remain anaemic and in addition are exposed to the risks of transfusion, such as viral infection, iron overload and problems associated with red cell antibody formation. The erythropoietin gene has been cloned and recombinant human erythropoietin (rHuEPO) is now marketed under the generic name epoetin. In this article we discuss the use of epoetin to treat anaemia in patients with renal failure and other potentially responsive conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
